| Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib D Marin, A Bazeos, FX Mahon, L Eliasson, D Milojkovic, M Bua, ... Journal of clinical oncology 28 (14), 2381, 2010 | 1127 | 2010 |
| Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis H De Lavallade, JF Apperley, JS Khorashad, D Milojkovic, AG Reid, ... Journal of Clinical Oncology 26 (20), 3358-3363, 2008 | 714 | 2008 |
| Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings R Szydlo, JM Goldman, JP Klein, RP Gale, RC Ash, FH Bach, BA Bradley, ... Journal of clinical oncology 15 (5), 1767-1777, 1997 | 610 | 1997 |
| Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase … D Marin, AR Ibrahim, C Lucas, G Gerrard, L Wang, RM Szydlo, RE Clark, ... Journal of Clinical Oncology 30 (3), 232, 2012 | 594 | 2012 |
| Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC T Vulliamy, A Marrone, R Szydlo, A Walne, PJ Mason, I Dokal Nature genetics 36 (5), 447-449, 2004 | 547 | 2004 |
| Soluble receptor activator of nuclear factor κB ligand–osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index E Terpos, R Szydlo, JF Apperley, E Hatjiharissi, M Politou, J Meletis, ... Blood 102 (3), 1064-1069, 2003 | 507 | 2003 |
| Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy AR Ibrahim, L Eliasson, JF Apperley, D Milojkovic, M Bua, R Szydlo, ... Blood, The Journal of the American Society of Hematology 117 (14), 3733-3736, 2011 | 396 | 2011 |
| Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia F Dazzi, RM Szydlo, C Craddock, NCP Cross, J Kaeda, A Chase, ... Blood, The Journal of the American Society of Hematology 95 (1), 67-71, 2000 | 394 | 2000 |
| Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year period DG Savage, RM Szydlo, JM Goldman British journal of haematology 96 (1), 111-116, 1997 | 386 | 1997 |
| Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey N Salooja, RM Szydlo, G Socie, B Rio, R Chatterjee, P Ljungman, ... The Lancet 358 (9278), 271-276, 2001 | 369 | 2001 |
| Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia F Dazzi, RM Szydlo, NCP Cross, C Craddock, J Kaeda, E Kanfer, ... Blood, The Journal of the American Society of Hematology 96 (8), 2712-2716, 2000 | 324 | 2000 |
| Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT C Crawley, M Lalancette, R Szydlo, M Gilleece, K Peggs, S Mackinnon, ... Blood 105 (11), 4532-4539, 2005 | 287 | 2005 |
| Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first 2 years DI Marks, JO Cullis, KN Ward, S Lacey, R Szydlo, TP Hughes, ... Annals of internal medicine 119 (3), 207-214, 1993 | 250 | 1993 |
| Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase [see comments] JM Goldman, R Szydlo, MM Horowitz, RP Gale, RC Ash, K Atkinson, ... | 248 | 1993 |
| Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT C Crawley, R Szydlo, M Lalancette, A Bacigalupo, A Lange, M Brune, ... Blood 106 (9), 2969-2976, 2005 | 238 | 2005 |
| Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the … F Van Rhee, RM Szydlo, J Hermans, A Devergie, F Frassoni, W Arcese, ... Bone marrow transplantation 20 (7), 553-560, 1997 | 211 | 1997 |
| Serum levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) correlate with the extent of bone disease and survival in patients with multiple myeloma E Terpos, M Politou, R Szydlo, JM Goldman, JF Apperley, A Rahemtulla British journal of haematology 123 (1), 106-109, 2003 | 200 | 2003 |
| Early detection of BCR-ABL transcripts by quantitative reverse transcriptase–polymerase chain reaction predicts outcome after allogeneic stem cell transplantation … E Olavarria, E Kanfer, R Szydlo, J Kaeda, K Rezvani, K Cwynarski, ... Blood, The Journal of the American Society of Hematology 97 (6), 1560-1565, 2001 | 198 | 2001 |
| Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression JS Khorashad, H De Lavallade, JF Apperley, D Milojkovic, AG Reid, ... Journal of clinical oncology 26 (29), 4806, 2008 | 197 | 2008 |
| Serum concentrations of Dickkopf‐1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation MC Politou, DJ Heath, A Rahemtulla, R Szydlo, A Anagnostopoulos, ... International journal of cancer 119 (7), 1728-1731, 2006 | 186 | 2006 |
Charles CraddockProfessor of Haemato-oncology, University of Warwick在 uhb.nhs.uk 的电子邮件经过验证
